Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Honebuto Draft Fails to Clear LDP, Renewed Discussions Set for June 3
June 2, 2022
- Govt’s Draft Grand Design for New Capitalism Vows to Spur Biotechnology Innovation
June 1, 2022
- Honebuto Draft Makes No Mention of Off-Year Re-Pricing or Buffer Zone, Calls for Stronger Drug Discovery Capabilities
June 1, 2022
- ViiV’s Vocabria, Janssen’s Rekambys for HIV to Join NHI Price List on June 8
June 1, 2022
- Post-Launch Safety Steps to Be More Important with Emergency Approval: Official
May 31, 2022
- Japan Panel OKs Taiho’s GIST Med, ViiV/Janssen’s HIV Combo and More for Approval
May 31, 2022
- 7 New Probable Cases of Pediatric Hepatitis Reported in Japan
May 31, 2022
- Janssen’s COVID-19 Vaccine in Line for Japan Approval, No Supply Deal Signed
May 31, 2022
- Lawmakers’ League on Vaccines Urges Enhanced R&D System for Homegrown Jabs
May 30, 2022
- Orphan Tag Granted for Eisai’s ALS Drug, 3 Other APIs
May 30, 2022
- Deregulation Panel Urges Better Data Infrastructure, DCT Promotion to Boost Drug Discovery in Japan
May 30, 2022
- Japan Approves Additional Indications, Dosages for Rinvoq, Adcetris, Rozex, and More
May 27, 2022
- Japan Begins Second COVID Booster for Age 60-Plus, High-Risk Adults
May 26, 2022
- MOF Panel Nudges Full Annual Drug Re-Pricing, Phase-Out for 2% Buffer Zone
May 26, 2022
- Japan Panel OKs Risk Management Measures for Potential Revlimid Generics
May 25, 2022
- MHLW to Issue Guidances on eConsent, Drug Delivery for Virtual Clinical Trials: Official
May 25, 2022
- Japan Regulators Warn of Monkeypox Cases
May 25, 2022
- MHLW Clarifies LVEF-Related Labeling Rule for Heart Failure Drugs: Q&A
May 24, 2022
- G7 Health Ministers Unite for Boosting Measures for Future Pandemics, AMR
May 24, 2022
- 2 mg Pen of Supply-Crippled Ozempic, 3rd Avastin Biosimilar Get Japan Listing
May 24, 2022
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…